Benefits of uric acid-lowering medication after bariatric surgery in patients with gout.
Bariatric surgery
Gout
Hyperuricemia
SUA
Uric acid-lowering medication
Journal
BMC surgery
ISSN: 1471-2482
Titre abrégé: BMC Surg
Pays: England
ID NLM: 100968567
Informations de publication
Date de publication:
14 Jun 2024
14 Jun 2024
Historique:
received:
15
01
2024
accepted:
06
06
2024
medline:
15
6
2024
pubmed:
15
6
2024
entrez:
14
6
2024
Statut:
epublish
Résumé
Patients with gout are at risk for increased serum uric acid (SUA) levels and gout attacks in the short term after undergoing bariatric surgery, and the purpose of this study was to evaluate the benefits of short-term treatment with uric acid-lowering medication after bariatric surgery for the control of gout attacks and SUA levels in patients with gout. 71 patients who underwent SG from January 2020 to December 2022 were prospectively included. These patients were diagnosed with hyperuricemia before surgery and had a history of gout attacks. Patients were classified into a drug-treatment group (DTG, n = 32) and a non-drug-treatment group (NDTG, n = 39) according to whether they took uric acid-lowering medication after surgery. Changes in the number of gout attacks, body mass index (BMI), and SUA levels at 1 week, 1 month, 3 months, and 6 months after bariatric surgery were measured in both groups. In the DTG, 22 patients (68.8%) experienced an increase in SUA within 1 week, 3 patients (9.4%) had an acute attack of gout within the first month, and no patients had a gout attack thereafter. In the NDTG, 35 patients (89.7%) experienced an increase in SUA within 1 week, 7 patients (17.9%) had an acute gout attack within the first month, and 4 patients (10.3%) experienced gout attacks between month 1 and month 3 postoperatively. Both groups were free of gout attacks between the 3rd and 6th postoperative month and showed a significant decrease in SUA and BMI by the sixth month. In patients with gout, continued use of uric acid-lowering medication after bariatric surgery is beneficial in reducing the number of gout attacks and the risk of rising SUA.
Sections du résumé
BACKGROUND/PURPOSE
OBJECTIVE
Patients with gout are at risk for increased serum uric acid (SUA) levels and gout attacks in the short term after undergoing bariatric surgery, and the purpose of this study was to evaluate the benefits of short-term treatment with uric acid-lowering medication after bariatric surgery for the control of gout attacks and SUA levels in patients with gout.
METHODS
METHODS
71 patients who underwent SG from January 2020 to December 2022 were prospectively included. These patients were diagnosed with hyperuricemia before surgery and had a history of gout attacks. Patients were classified into a drug-treatment group (DTG, n = 32) and a non-drug-treatment group (NDTG, n = 39) according to whether they took uric acid-lowering medication after surgery. Changes in the number of gout attacks, body mass index (BMI), and SUA levels at 1 week, 1 month, 3 months, and 6 months after bariatric surgery were measured in both groups.
RESULTS
RESULTS
In the DTG, 22 patients (68.8%) experienced an increase in SUA within 1 week, 3 patients (9.4%) had an acute attack of gout within the first month, and no patients had a gout attack thereafter. In the NDTG, 35 patients (89.7%) experienced an increase in SUA within 1 week, 7 patients (17.9%) had an acute gout attack within the first month, and 4 patients (10.3%) experienced gout attacks between month 1 and month 3 postoperatively. Both groups were free of gout attacks between the 3rd and 6th postoperative month and showed a significant decrease in SUA and BMI by the sixth month.
CONCLUSION
CONCLUSIONS
In patients with gout, continued use of uric acid-lowering medication after bariatric surgery is beneficial in reducing the number of gout attacks and the risk of rising SUA.
Identifiants
pubmed: 38877436
doi: 10.1186/s12893-024-02472-6
pii: 10.1186/s12893-024-02472-6
doi:
Substances chimiques
Uric Acid
268B43MJ25
Gout Suppressants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
186Subventions
Organisme : Bureau of Science and Technology Nanchong Municipality
ID : 22SXQT0126
Organisme : Research and Development Program of Affiliated Hospital of North Sichuan Medical College
ID : 2022SK011
Organisme : National Natural Science Foundation of China
ID : 82070535
Organisme : Natural Science Foundation of Sichuan Province
ID : 2022NSFSC0706
Organisme : Science and Technology Program of the Sichuan Provincial Health and Wellness Commission
ID : 23LCYJ031
Informations de copyright
© 2024. The Author(s).
Références
Oda M, Satta Y, Takenaka O, Takahata N. Loss of urate oxidase activity in hominoids and its evolutionary implications [J]. Mol Biol Evol. 2002;19(5):640–53. PMID: 11961098.
pubmed: 11961098
doi: 10.1093/oxfordjournals.molbev.a004123
Qiu L, Cheng XQ, Wu J et al. Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and Northeastern Chinese provinces [J]. BMC Public Health, 2013,13:664. PMID: 23866159.
So A, Thorens B. Uric acid transport and disease [J]. J Clin Invest. 2010;120(6):1791–9. PMID: 20516647.
pubmed: 20516647
pmcid: 2877959
doi: 10.1172/JCI42344
Yanai H, Adachi H, Hakoshima M, Katsuyama H. Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease [J]. Int J Mol Sci, 2021,22(17). PMID: 34502127.
Ren Q, Tao S, Guo F, et al. Natural flavonol fisetin attenuated hyperuricemic nephropathy via inhibiting IL-6/JAK2/STAT3 and TGF-β/SMAD3 signaling [J]. Phytomedicine. 2021;87:153552. PMID: 33994251.
pubmed: 33994251
doi: 10.1016/j.phymed.2021.153552
Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout [J] Lancet. 2021;397(10287):1843–55. PMID: 33798500.
pubmed: 33798500
doi: 10.1016/S0140-6736(21)00569-9
Cicero AFG, Fogacci F, Kuwabara M, Borghi C. Therapeutic strategies for the treatment of chronic hyperuricemia: an evidence-based update [J]. Med (Kaunas), 2021,57(1). PMID: 33435164.
Cicero AFG, Fogacci F, Cincione RI, Tocci G, Borghi C. Clinical effects of Xanthine oxidase inhibitors in Hyperuricemic patients [J]. Med Princ Pract. 2021;30(2):122–30. PMID: 33040063.
pubmed: 33040063
doi: 10.1159/000512178
Hassan W, Shrestha P, Sumida K, et al. Association of Uric Acid-lowering therapy with incident chronic kidney disease [J]. JAMA Netw Open. 2022;5(6):e2215878. PMID: 35657621.
pubmed: 35657621
pmcid: 9166229
doi: 10.1001/jamanetworkopen.2022.15878
Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature [J]. Curr Opin Rheumatol. 2011;23(2):192–202. PMID: 21285714.
pubmed: 21285714
pmcid: 4104583
doi: 10.1097/BOR.0b013e3283438e13
Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study [J]. Arch Intern Med. 2005;165(7):742–8. PMID: 15824292.
pubmed: 15824292
doi: 10.1001/archinte.165.7.742
He Y, Hara H. Mechanism and regulation of NLRP3 inflammasome activation [J]. Trends Biochem Sci. 2016;41(12):1012–21. PMID: 27669650.
pubmed: 27669650
pmcid: 5123939
doi: 10.1016/j.tibs.2016.09.002
Lu J, Bai Z, Chen Y, et al. Effects of bariatric surgery on serum uric acid in people with obesity with or without hyperuricaemia and gout: a retrospective analysis [J]. Rheumatology (Oxford). 2021;60(8):3628–34. PMID: 33394025.
pubmed: 33394025
doi: 10.1093/rheumatology/keaa822
Romero-Talamás H, Daigle CR, Aminian A, Corcelles R, Brethauer SA, Schauer PR. The effect of bariatric surgery on gout: a comparative study [J]. Surg Obes Relat Dis. 2014;10(6):1161–5. PMID: 24935177.
pubmed: 24935177
doi: 10.1016/j.soard.2014.02.025
Dalbeth N, Chen P, White M, et al. Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study [J]. Ann Rheum Dis. 2014;73(5):797–802. PMID: 24255548.
pubmed: 24255548
doi: 10.1136/annrheumdis-2013-203970
Friedman JE, Dallal RM, Lord JL. Gouty attacks occur frequently in postoperative gastric bypass patients [J]. Surg Obes Relat Dis. 2008;4(1):11–3. PMID: 18065292.
pubmed: 18065292
doi: 10.1016/j.soard.2007.09.012
Xu C, Wen J, Yang H, et al. Factors influencing early serum uric acid fluctuation after bariatric surgery in patients with hyperuricemia [J]. Obes Surg. 2021;31(10):4356–62. PMID: 34309788.
pubmed: 34309788
doi: 10.1007/s11695-021-05579-4
Antozzi P, Soto F, Arias F, et al. Development of acute gouty attack in the morbidly obese population after bariatric surgery [J]. Obes Surg. 2005;15(3):405–7. PMID: 15826477.
pubmed: 15826477
doi: 10.1381/0960892053576802
Neogi T, Jansen TL, Dalbeth N, et al. 2015 gout classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative [J]. Arthritis Rheumatol. 2015;67(10):2557–68. PMID: 26352873.
pubmed: 26352873
pmcid: 4566153
doi: 10.1002/art.39254
Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. Natl Health Nutr Examination Surv [J] Jama. 2000;283(18):2404–10. PMID: 10815083.
Appropriate body-mass. Index for Asian populations and its implications for policy and intervention strategies [J]. Lancet. 2004;363(9403):157–63. PMID: 14726171.
doi: 10.1016/S0140-6736(03)15268-3
MA, McAdams DeMarco JW, Maynard AN, Baer, et al. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the atherosclerosis risk in communities cohort study [J]. Arthritis Rheum. 2012;64(1):121–9. PMID: 22031222.
doi: 10.1002/art.33315
Ticinesi A, Nouvenne A, Borghi L, Meschi T. Water and other fluids in nephrolithiasis: state of the art and future challenges [J]. Crit Rev Food Sci Nutr. 2017;57(5):963–74. PMID: 25975220.
pubmed: 25975220
doi: 10.1080/10408398.2014.964355
Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors [J]. Nat Rev Rheumatol. 2015;11(11):649–62. PMID: 26150127.
pubmed: 26150127
doi: 10.1038/nrrheum.2015.91
Campion EW, Glynn RJ. Asymptomatic hyperuricemia. Risks and consequences in the normative aging study [J]. Am J Med. 1987;82(3):421–6. PMID: 3826098.
pubmed: 3826098
doi: 10.1016/0002-9343(87)90441-4
Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia [J]. Curr Opin Rheumatol, 2013,25(2):210-6. PMID: 23370374.
Yue JR, Huang CQ, Dong BR. Association of serum uric acid with body mass index among long-lived Chinese [J]. Exp Gerontol. 2012;47(8):595–600. PMID: 22595700.
pubmed: 22595700
doi: 10.1016/j.exger.2012.05.008
Su P, Hong L, Zhao Y, Sun H, Li L. Relationship between Hyperuricemia and Cardiovascular Disease Risk factors in a Chinese Population: a cross-sectional study [J]. Med Sci Monit. 2015;21:2707–17. PMID: 26364955.
pubmed: 26364955
pmcid: 4576929
doi: 10.12659/MSM.895448
Strilchuk L, Fogacci F, Cicero AF. Safety and tolerability of available urate-lowering drugs: a critical review [J]. Expert Opin Drug Saf. 2019;18(4):261–71. PMID: 30915866.
pubmed: 30915866
doi: 10.1080/14740338.2019.1594771
Zhu Y, Zhang Y, Choi HK. The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: the multiple risk factor intervention trial [J]. Rheumatology (Oxford). 2010;49(12):2391–9. PMID: 20805117.
pubmed: 20805117
doi: 10.1093/rheumatology/keq256
Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study [J]. Ann Rheum Dis. 2000;59(7):539–43. PMID: 10873964.
pubmed: 10873964
pmcid: 1753185
doi: 10.1136/ard.59.7.539
Richette P, Poitou C, Manivet P, et al. Weight loss, Xanthine Oxidase, and serum urate levels: a prospective longitudinal study of obese patients [J]. Arthritis Care Res (Hoboken). 2016;68(7):1036–42. PMID: 26844534.
pubmed: 26844534
doi: 10.1002/acr.22798
Maglio C, Peltonen M, Neovius M, et al. Effects of bariatric surgery on gout incidence in the Swedish obese subjects study: a non-randomised, prospective, controlled intervention trial [J]. Ann Rheum Dis. 2017;76(4):688–93. PMID: 28076240.
pubmed: 28076240
doi: 10.1136/annrheumdis-2016-209958
Richette P, Poitou C, Garnero P, et al. Benefits of massive weight loss on symptoms, systemic inflammation and cartilage turnover in obese patients with knee osteoarthritis [J]. Ann Rheum Dis. 2011;70(1):139–44. PMID: 20980288.
pubmed: 20980288
doi: 10.1136/ard.2010.134015
Dalbeth N, Pool B, Yip S, Cornish J, Murphy R. Effect of bariatric surgery on the inflammatory response to monosodium urate crystals: a prospective study [J]. Ann Rheum Dis. 2013;72(9):1583–4. PMID: 23666933.
pubmed: 23666933
doi: 10.1136/annrheumdis-2013-203545
Baldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome [J]. Diabetes. 2011;60(4):1258–69. PMID: 21346177.
pubmed: 21346177
pmcid: 3064099
doi: 10.2337/db10-0916
Kang EH, Lee EY, Lee YJ, Song YW, Lee EB. Clinical features and risk factors of postsurgical gout [J]. Ann Rheum Dis. 2008;67(9):1271–5. PMID: 17998214.
pubmed: 17998214
doi: 10.1136/ard.2007.078683
Craig MH, Poole GV, Hauser CJ. Postsurgical gout [J]. Am Surg. 1995;61(1):56–9. PMID: 7832383.
pubmed: 7832383
[Chinese expert consensus on precision obesity metabolic surgery. (2022 edition)] [J]. Zhonghua Wei Chang Wai Ke Za Zhi, 2022,25(10):841–851. PMID: 36245107.
RK Marwah. Comorbidities in gouty arthritis [J]. J Investig Med. 2011;59(8):1211–20. PMID: 22064605.
doi: 10.2310/JIM.0b013e318239f660
ZoomForward2022: European Congress on Obesity [J]. Obes Facts. 2022,15 Suppl 1:1-240. PMID: 35500564.
Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for Metabolic and bariatric surgery (ASMBS) and International Federation for the Surgery of Obesity and metabolic disorders (IFSO): indications for metabolic and bariatric surgery [J]. Surg Obes Relat Dis. 2022;18(12):1345–56. PMID: 36280539.
pubmed: 36280539
doi: 10.1016/j.soard.2022.08.013
Tana C, Busetto L, Vincenzo AD, et al. Management of hyperuricemia and gout in obese patients undergoing bariatric surgery [J]. Postgrad Med. 2018;130(6):523–35. PMID: 29888674.
pubmed: 29888674
doi: 10.1080/00325481.2018.1485444
Bal BS, Finelli FC, Shope TR, Koch TR. Nutritional deficiencies after bariatric surgery [J]. Nat Rev Endocrinol. 2012;8(9):544–56. PMID: 22525731.
pubmed: 22525731
doi: 10.1038/nrendo.2012.48
Bettini S, Belligoli A, Fabris R, Busetto L. Diet approach before and after bariatric surgery [J]. Rev Endocr Metab Disord. 2020;21(3):297–306. PMID: 32734395.
pubmed: 32734395
pmcid: 7455579
doi: 10.1007/s11154-020-09571-8
Gasmi A, Bjørklund G, Mujawdiya PK, et al. Micronutrients deficiences in patients after bariatric surgery [J]. Eur J Nutr. 2022;61(1):55–67. PMID: 34302218.
pubmed: 34302218
doi: 10.1007/s00394-021-02619-8
Brocks DR, Ben-Eltriki M, Gabr RQ, Padwal RS. The effects of gastric bypass surgery on drug absorption and pharmacokinetics [J]. Expert Opin Drug Metab Toxicol. 2012;8(12):1505–19. PMID: 22998066.
pubmed: 22998066
doi: 10.1517/17425255.2012.722757